aTyr Pharma CFO sells 1,558 shares at $0.976

aTyr Pharma’s Chief Financial Officer, Jill Marie Broadfoot, reported routine equity compensation activity and a small share sale.

Rhea-AI Filing Summary

aTyr Pharma’s Chief Financial Officer, Jill Marie Broadfoot, reported routine equity compensation activity and a small share sale. On February 3, 2026, 3,750 restricted stock units vested and converted into the same number of common shares, originally granted on February 3, 2022.

On February 4, 2026, she sold 1,558 common shares at $0.976 per share to cover tax withholding obligations related to this RSU vesting. After these transactions, she directly held 37,296 shares of aTyr Pharma common stock, and no restricted stock units from this grant remained outstanding.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Broadfoot Jill Marie

Role Chief Financial Officer

Sold 1,558 shs ($2K)

Approx. gross sale proceeds $2K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	1,558	$0.976	$2K
Exercise	Restricted Stock Unit	3,750	$0.00	$0.00
Exercise	Common Stock	3,750	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 37,296 shares (Direct)

Footnotes (4)

1. F1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
2. F2. Restricted stock units convert into common stock on a one-for-one basis.
3. F3. Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
4. F4. The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did aTyr Pharma (ATYR) report for its CFO?

aTyr Pharma reported that CFO Jill Marie Broadfoot had 3,750 restricted stock units vest into common shares, then sold 1,558 shares. The sale was made at $0.976 per share to satisfy tax withholding obligations related to the RSU vesting.

How many aTyr Pharma (ATYR) shares did the CFO sell and at what price?

The CFO sold 1,558 aTyr Pharma common shares at a price of $0.976 per share. This sale occurred on February 4, 2026 and was conducted to cover tax withholding tied to the recent vesting of restricted stock units.

How many aTyr Pharma (ATYR) shares does the CFO own after the reported transactions?

Following the reported transactions, CFO Jill Marie Broadfoot directly owns 37,296 aTyr Pharma common shares. This balance reflects the vesting of 3,750 restricted stock units and the subsequent sale of 1,558 shares for tax withholding purposes in early February 2026.

What happened to the 3,750 restricted stock units reported for aTyr Pharma (ATYR)?

The 3,750 restricted stock units fully vested and converted into 3,750 aTyr Pharma common shares on February 3, 2026. These RSUs were originally granted on February 3, 2022 and were structured to convert into common stock on a one-for-one basis upon vesting.

Why did the aTyr Pharma (ATYR) CFO sell shares after RSU vesting?

The CFO sold shares to satisfy tax withholding obligations triggered by the partial vesting of restricted stock units granted on February 3, 2022. Specifically, she sold 1,558 common shares at $0.976 per share on February 4, 2026 to cover these tax-related requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 07:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Broadfoot Jill Marie

(Last) (First) (Middle)

10240 SORRENTO VALLEY ROAD

SUITE 300

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		M(1)		3,750	A	(2)	38,854	D
Common Stock	02/04/2026		S(3)		1,558	D	$0.976	37,296	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(2)	02/03/2026		M			3,750	(4)	(4)	Common Stock	3,750	$0	0	D

Explanation of Responses:

1. Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.

2. Restricted stock units convert into common stock on a one-for-one basis.

3. Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.

4. The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.

	/s/ Nancy E. Denyes, attorney-in-fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.